The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients.The vaccine composition of the present invention has as active principle a chemical conjugated between the human recombinant Epidermal Growth Factor (hrEGF) and the P64K recombinant protein. In another embodiment, the present invemtion relates to the conjugation procedure to obtain, a chemical conjugated under controlled and reproducible parameters.In a preferred embodiment, the present invention relates to the procedure for purifying the chemical conjugated with a higher purity of the therapeutical vaccine composition, and a surprisingly increased immunogenic activity, inducing a significant increase of the anti-EGF antibody titers in humans.Additionally the present invention provides the methodology to obtain a vaccine composition in several dose presentations (total milligrams of conjugated EGF-P64K/vial). The versatility of the dose presentation allows increasing the immunization dose per patient, without increasing the frequency of injections and / or immunization sites.Besides, the present invention relates to a sanitary procedure for obtaining a vaccine composition for parenteral route in the cancer therap.本發明關於生物技術領域且特別關於人體健康。更具體地說，本發明關於供癌症病患治療用之疫苗組成物。本發明之疫苗組成物具有作為活性成分之人重組表皮生長因子(hrEGF)與P64K重組蛋白質之化學共軛物。在另一實施態樣中，本發明關於在受控制及可重現之參數下製備化學共軛物之共軛方法。在一較佳實施態樣中，本發明關於純化化學共軛物之方法，其生成較高純度之治療性疫苗組成物及意外地增加免疫原活性，且誘發人抗EGF抗體力價之顯著增加。另外，本發明提供製備多種劑量表示法(每瓶中EGF－P64K共軛物之總毫克數)之疫苗組成物之方法。該劑量表示法之多樣性係使每位病患之免疫劑量得以提高，且無需增加注射頻率及/或免疫部位。此外，本發明關於製備供癌症治療的非經腸途徑使用之疫苗組成物之衛生方法。
